Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Non-Interventional Study in Participants With Indolent Systemic Mastocytosis (ISM) in Germany
Sponsor: Blueprint Medicines Corporation
Summary
This is a non-interventional study assessing the effectiveness of avapritinib (BLU-285) in the management of ISM in real-world settings in Germany. The study also seeks to address the existing data gap in the natural history and management of participants with ISM. The study is designed to follow each participant up to a maximum of 24 months.
Official title: A Prospective Non-Interventional Study to Describe the Effectiveness of Avapritinib (BLU-285), a Selective KIT Mutation-Targeted Tyrosine Kinase Inhibitor, in Patients With Indolent Systemic Mastocytosis and Symptoms That Are Not Adequately Controlled With Symptomatic Treatments in Real-World Settings
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
80
Start Date
2025-12-09
Completion Date
2028-12-01
Last Updated
2026-02-10
Healthy Volunteers
No
Conditions
Interventions
Avapritinib
Avapritinib will be administered as an oral tablet.
Locations (4)
Charité Universitätmedizin Berlin, Klinik für Dermatologie, Venerologie und Allergologie
Berlin, Germany
Universitätsklinikum Carl Gustav Carus Dresden Klinik und Poliklinik für Dermatologie
Dresden, Germany
University Medical Center Goettingen - Georg August University of Goettingen
Göttingen, Germany
Universitats-Hautklinik Tubingen, Studienzentrum lmmundermatologie
Tübingen, Germany